Shares in AnaptysBio, a San Diego-based biotech focused on delivering innovative immunology therapeutics, was trading 19% ...

Massachusetts, USA-based cell therapy specialist Abcuro today announced the closing of a $200 million Series C financing.

An Expert View from Nick Petschek, EMEA managing director at global change management firm Kotter International.

Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech ...

US pharma major AbbVie has announced a deal with Xilio Therapeutics, more than doubling the latter’s share price.

At least 90% of drugs from the list of vital medicines in Russia will be of domestic origin already by the end of 2025, ...

Biogen reported fourth-quarter 2024 earnings that surpassed analysts' expectations, driven by strong sales of new product ...

US biotech major Gilead Sciences was trading nearly 5% higher in Wednesday’s pre-market trading after presenting its fourth ...

England’s National Institute for Health and Care Excellence (NICE), and Canada’s Drug Agency (CDA-AMC) have formed the Health Economics Methods Advisory (HEMA) initiative. The goal of HEMA is to ...

Belgium’s largest drugmaker UCB today released long-term data from the BE HEARD^ trials for Bimzelx (bimekizumab) in moderate ...

US biotech Voyager Therapeutics saw its shares close down 21% at $4.20 on Tuesday, after it revealed its decision to assess ...

A federal judge has temporarily blocked the National Institutes of Health (NIH) from implementing research funding cuts in 22 ...